Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents
Allergy · 2025
DOI: 10.1111/all.16646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Yusuke Okubo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Allergens, Rhinitis, Allergic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Japan Science and Technology Agency, Cabinet Office, Government of Japan, Ministry of Health, Labour and Welfare.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Sublingual allergen immunotherapy (SLIT) is a safe and effective treatment of allergic rhinitis, and its use has been increasing in recent years. Although several randomized and observational studies showed the effectiveness of SLIT among adults and children aged > 12 years, its extent remains unclear in nationwide routine healthcare settings for school‐aged children.
Methods
We conducted a propensity score (PS)‐matched cohort study using a nationwide administrative database. Data from 13,449 individuals who received SLIT for house dust mites between 2015 and 2021 were extracted and matched with data from 1,732,961 individuals who did not. The PS‐matching procedure created 10,985 pairs and followed them for three years, totaling 812,795 person‐months. Then, we compared healthcare costs, resource use, and prescriptions between the SLIT and control groups over the three years.
Results
The introduction of SLIT was associated with an 8.9% reduction in antibiotic use (95% CI, 12.0% to 34.7%) and a 65.2% reduction in hospitalizations (95% CI, 52.8% to 74.4%), as well as a 44.1% increase in health resource utilization (95% CI, 40.7% to 47.6%), with minimal impact on overall healthcare costs (+8.9% [95% CI, −12.0% to +34.7%]) over the three‐year follow‐up period. Similar findings were observed in event‐study design and intention‐to‐treat analyses, as well as in age‐stratified analyses (ages 5–10 years and 11–19 years).
Conclusions
The introduction of SLIT for house dust mites was associated with a reduction in antibiotic prescriptions and hospitalizations among children aged 5–19 years with minimal impact on healthcare costs, demonstrating sustained benefits over three years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Social Medicine, National Center for Child Health and Development, Tokyo, Japan.
- Allergy Center, NHO Mie National Hospital, Tsu, Mie, Japan.
- Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
- Division of Otorhinolaryngology Head & Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan.
- Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.
- Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
ORCID-Profile: Hideaki Morita
Förderung
- Japan Science and Technology Agency
- Cabinet Office, Government of Japan
- Ministry of Health, Labour and Welfare
Zitieren
APA
Okubo, Y., Kuwabara, Y., Sato, S., Sakashita, M., & Morita, H. (2025). Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents. Allergy. https://doi.org/10.1111/all.16646
Vancouver
Okubo Y, Kuwabara Y, Sato S, Sakashita M, Morita H. Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents. Allergy. 2025. doi:10.1111/all.16646
BibTeX
@article{Okubo2025,
author = {Okubo, Yusuke and Kuwabara, Yu and Sato, Sakura and Sakashita, Masafumi and Morita, Hideaki},
title = {Real‐World Effectiveness for Sublingual Allergen Immunotherapy Among School‐Aged Children and Adolescents},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16646}
}
EUVIMED